top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$136.4M

Burn Rate (Qtr)

$24.0M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Create Free Account Now

Loading Catalysts...

search in progress

Pipeline powered by

URGN

BPIQ_Logo_RGB-01.jpg

Company Profile

UroGen Pharma is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases.

Recent Posts

See what the community is saying - click to see full post.

J.P. Morgan Healthcare Conference

Q2 Corporate Quarterly Updates: Small and Mid-Cap Biotech Companies to Watch

URGN - Complete & Durable Responses in Phase 2b Final Results for UGN-102 in Patients with Low-Grade Non-Muscle Invasive Bladder Cancer

URGN - Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021

URGN - UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

URGN - UGN-101 - UTUC

bottom of page